Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

ORIN1001

Status:

Phase 1

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Oral Drug

Funder Type:

Industry

Drug Details

ORIN1001 is an investigational first-in-class small molecule drug that has a novel molecular target, novel mechanism of action and a novel chemical structural class and identity.

Study Purpose

This Phase 1b trial is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of oral ORIN1001 at 25 mg, 50 mg or 100 mg administered daily for up to 28 days in adult subjects with idiopathic pulmonary fibrosis (IPF) alone or in conjunction with local Standard of Care for IPF (pirfenidone or nintedanib).

Find a Clinical Trial